Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

Inclusion Criteria

• •Background disease other than lymphoma or multiple myeloma (MM)
• •Are younger than 18 years of age.
• •Received transplant using ex vivo plerixafor-mobilised cells (umbilical cord cell, peripheral blood (PB), bone marrow (BM) cell collection)
• •Received treatment with plerixafor alone (i.e., without granulocyte colony stimulating factor (G-CSF))
• •Contraindication for G-CSF
• •Transplants using plerixafor-mobilised cells from allogeneic donor
• •Received transplant using plerixafor-mobilised bone marrow cells
• •Routes of plerixafor administration other than subcutaneous
• •Patients whose cells do not mobilize poorly
• •Other